N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called NuvecĀ®.
We spoke with Nigel today and asked about the progress the company is making and shareholders question.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use NuvecĀ® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
https://www.share-talk.com/nigel-theobald-ceo-of-n4-pharma-plc-n4p-l-interview/
https://www.share-talk.com/nigel-theobald-ceo-of-n4-pharma-plc-n4p-l-interview/
Listen On
Also Listen
-
Zak Mir talks to Ryan Mee, CEO of Fulcrum Metals
Zak Mir talks to Ryan Mee, CEO of Fulcrum Metals, in the wake of the Panther Met -
Zak Mir talks to Segun Lawson, President & CEO of Thor Explorations
Zak Mir talks to Segun Lawson, CEO of Thor Explorations. The company provided an -
Zak Mir talks to Mark Routh, CEO of Prospex Energy
Zak Mir talks to Mark Routh, CEO of Prospex Energy, an AIM-quoted investment com -
Transforming Biotech: Insights from Tim McCarthy, CEO of ImmuPharma
ImmuPharma PLC (AIM: IMM) CEO Tim McCarthy spoke with Zak Mir. In the world of b